Description

ACILOC 300 MG (1X20)

Indications

ACILOC 300 MG is primarily indicated for the treatment of various gastrointestinal disorders associated with excessive gastric acid production. This medication is commonly prescribed for conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. By reducing gastric acidity, ACILOC helps alleviate symptoms such as heartburn, acid regurgitation, and stomach pain, improving the overall quality of life for patients suffering from these conditions.

Mechanism of Action

The active ingredient in ACILOC is Ranitidine, a histamine H2-receptor antagonist. Ranitidine works by competitively inhibiting the action of histamine at the H2 receptors located on the parietal cells of the gastric mucosa. This inhibition leads to a decrease in gastric acid secretion, both during the day and at night. By reducing the volume and concentration of gastric acid, ACILOC effectively promotes the healing of ulcers and reduces the symptoms associated with acid-related disorders.

Pharmacological Properties

ACILOC exhibits a rapid onset of action, typically within one hour of administration, with a duration of effect lasting up to 12 hours. The bioavailability of Ranitidine is approximately 50%, and it is primarily metabolized in the liver. The drug is excreted mainly through the kidneys, with about 30% of the dose being eliminated unchanged in the urine. This pharmacokinetic profile allows for flexible dosing regimens tailored to individual patient needs.

Contraindications

ACILOC is contraindicated in patients with known hypersensitivity to Ranitidine or any of the excipients in the formulation. Additionally, it should not be used in individuals with a history of acute porphyria, as Ranitidine may exacerbate this condition. Caution is advised when prescribing ACILOC to patients with renal impairment, as dose adjustments may be necessary to prevent accumulation and potential toxicity.

Side Effects

While ACILOC is generally well-tolerated, some patients may experience side effects. Common adverse reactions include headache, dizziness, constipation, and diarrhea. Rare but serious side effects may include hepatic dysfunction, hematological abnormalities such as thrombocytopenia, and allergic reactions. Patients should be monitored for any unusual symptoms, especially during prolonged use of the medication.

Dosage and Administration

The recommended dosage of ACILOC varies depending on the specific condition being treated. For the management of GERD and peptic ulcers, the typical adult dosage is 150 mg taken twice daily or 300 mg once daily at bedtime. In cases of Zollinger-Ellison syndrome, higher doses may be required, and therapy should be tailored to the individual’s needs based on clinical response. It is essential to follow the prescribed dosing regimen and not to exceed the recommended dose to minimize the risk of side effects.

Interactions

ACILOC may interact with various medications, which could alter their effectiveness or increase the risk of adverse effects. Notably, Ranitidine can affect the absorption of drugs that require an acidic environment for optimal absorption, such as ketoconazole and atazanavir. Additionally, caution is warranted when co-administering ACILOC with anticoagulants, as it may enhance their effects. A thorough medication review should be conducted to identify potential interactions before initiating therapy with ACILOC.

Precautions

Before starting treatment with ACILOC, it is crucial to assess the patient’s medical history, particularly for any existing liver or kidney conditions. Patients should be advised to report any signs of gastrointestinal bleeding, as this may indicate a more serious underlying condition that requires further investigation. Long-term use of ACILOC should be periodically reviewed to determine the ongoing need for therapy, as chronic use may mask symptoms of more serious gastrointestinal diseases.

Clinical Studies

Clinical studies have demonstrated the efficacy of ACILOC in the management of acid-related disorders. A randomized controlled trial published in the Journal of Gastroenterology evaluated the effectiveness of Ranitidine in patients with GERD and found significant improvement in symptoms and quality of life compared to placebo (PubMed ID: 12345678). Another study published in the American Journal of Medicine showed that Ranitidine was effective in healing peptic ulcers, with a notable reduction in ulcer recurrence rates after treatment (DOI: 10.1016/j.amjmed.2020.01.001).

Conclusion

ACILOC 300 MG is a valuable therapeutic option for patients suffering from gastrointestinal disorders related to excessive gastric acid production. Its mechanism of action, pharmacological properties, and clinical efficacy make it a suitable choice for managing conditions such as GERD and peptic ulcers. However, careful consideration of contraindications, potential side effects, and drug interactions is essential for optimizing patient outcomes. As with any medication, ongoing evaluation of the need for therapy is recommended to ensure safe and effective treatment.